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Abstract The M2 haplotype of the annexin A5 gene is a well-recognized predisposition factor for recurrent spontaneous abortion
(RSA). A recent publication by Nagirnaja et al. (2015) in PLoS One discusses the risk role of the M2 haplotype for RSA in cases com-
pared with controls of North European extraction and arrives at a negative result. As a number of previous and fairly recent studies
have supported the proposed involvement of the M2 haplotype in the cause of idiopathic RSA, this commentary aims to highlight
problematic issues in the above publication. It is the opinion of the authors that the study by Nagirnaja et al. (2015) does not gen-
erate adequate proof of the absence of RSA risk, attributable to carriage of the M2 haplotype.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Hereditary thrombophilia is considered to be one of several
causes of recurrent spontanous abortion (RSA), supported by
evidence of impaired placental perfusion caused by throm-
botic events. This cause is reﬂected in increased risk of adverse
pregnancy outcomes, reviewed in clinical studies and ini-
tially limited to genetic variants of blood coagulation factors
II (prothrombin) and V. In 2007, another proposed heredi-
tary factor for thrombophilia related RSA was identiﬁed,
termed “M2”, a haplotype in the proximal core promoter
region of the annexin A5 (ANXA5) gene, deﬁned as a constel-
lation of four single nucleotide polymorphisms (SNP),
rs112782763, rs28717001, rs28651243 and rs113588187
(Bogdanova et al., 2007). The haplotype, an RSA predisposi-
tion factor, RPRGL3, OMIM entry 614391, was conﬁrmed
through molecular cloning and direct sequencing of the rel-
evant amplicon clones, so the minor alleles’ action of all four
SNP comprising it manifested in reduced expression of a re-
porter gene compared with a background construct harbour-
ing all the major (normal) alleles, when using a functionally
representative cell line. Since then, more than 20 studies have
discussed and delivered evidence on the risk role of this
common ANXA5 genetic variant from retrospective and pro-
spective clinical studies on thrombophilia-related obstetric
complications in various ethnic backgrounds, and on its patho-
physiological expression as embryonic anticoagulant.
A recent study by Nagirnaja et al. (2015) describes a case-
control approach to the association of M2/ANXA5 with RSA
comparing patient and control groups of Northern European
extraction. Although the authors agree on the congruity of
the M2 haplotype, as constellation of the four SNP
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from a wealth of sequencing and microarray data, this infor-
mation is not new. They basically compare the M2 incidence
in 313 patients with unexplained RSA to a fertile women
control group of 214 participants from Estonia and Denmark
and arrive at the conclusion thatM2/ANXA5 is not a risk factor
for RSA in Northern Europe. After thorough analysis of the
results reported, several major and a minor issues in this pub-
lication remain that appear problematic in relation to the con-
clusions reached.
Major issues
Patient groups
The exclusion criteria for “unexplained recurrent miscar-
riage” as deﬁned by the Nagirnaja et al. (2015) did not take
into account fetal chromosomal abnormalities, known to be
the most common cause of early pregnancy losses. Accord-
ing to a fairly recent review on the subject, chromosomal
and submicroscopic genetic abnormalities on average are
prevalent in about 45% of early RSA samples. Early idio-
pathic RSA is caused mostly by chromosomal abnormalities
and, as shown recently, with only a residual spontaneous
abortion rate of 7% (Hodes-Wertz et al., 2012). Information
on chromosomal aberrations in the pregnancy losses of
patients who have experienced RSA in this study was not
available, so it is hard to accurately discriminate the effect
of the ANXA5 M2 haplotype from an elevated risk of chromo-
somal abnormalities in general. A recent study of RSA cases
from Estonia and Denmark has demonstrated genomic copy
number variations signiﬁcantly enriched in this particular
patient group and conferring an increased risk of RSA
(Nagirnaja et al., 2014).
Indeed, the risk of RSA attributed to M2 carriers from both
retrospective and prospective clinical cohorts and esti-
mated in Germans, for example, has been rather consis-
tent. Results were from a total of 600 patients who have
experienced RSA, largely pre-screened negative for fetal chro-
mosomal abnormalities among other well-known risk factors,
with 1123 control participants included in these studies
(Bogdanova et al., 2007; Rogenhofer et al., 2012, 2013a,
2013b, 2014; Tüttelmann et al., 2013).
A recent study examining the risk role ofM2/ANXA5 in the
most sizeable European RSA cohort (500 couples), conﬁrms
the risk role of the haplotype and sheds more light on allelic
dependence and interaction with additional pro-thrombotic
risk factors (Demetriou et al., 2015). This recent study, af-
ﬁrming the association of theANXA5 risk haplotypewith early,
but not late, RSA (as noted previously by Tüttelmann et al.,
2013), raises the question ofwhether 10.5% of Estonianwomen
and 22.9% of Danish women who had experienced both early
and late RSA, respectively (according to Table 4 in Nagirnaja
et al., 2015), should have been analysed separately from the
other patient cohorts that only experienced early spontane-
ous abortions.
Control groups
To arrive at a greater statistical power, without even men-
tioning population structure comparative genotyping, the
authors used imputation of M2/ANXA5 SNP data from the
German KORA S3 cohort (Holle et al, 2005), composed of 1644
participants. Despite the fact that controls in the KORA study
have been used inmany disease association studies, they have
some limitations. First, the controls do not adhere to the deﬁ-
nition of randompopulation controls, as they comprise of DNA
samples from blood donors, deﬁned as “healthy”, recruited
in the Augsburg area of Bavaria, South Germany. This pres-
ents methodological age, gender and status bias. In con-
trast, PopGen controls are true random population controls
as deﬁnedbyKrawczak et al. (2006). Second, there is a problem
with the haplotype reconstruction. Statistical derivation of
haplotypes from KORA genotype data usually results in inci-
dence overestimates, which are even greater when common
haplotypes are considered, owing tophase reconstructionerrors
that are inherent to array genotyping (Heid et al., 2005). Third,
from allM2/ANXA5 published research that conﬁrms the hap-
lotype as RSA risk factor, three original studies use random
population controls, according to their strict deﬁnition: seminal
publication on the risk role of M2/ANXA5 (Bogdanova et al.,
2007) (and all subsequent publications utilizing the PopGen
cohort); the study by Tüttelmann et al. (2013), using a popu-
lation sample from the National Genetic Laboratory in Soﬁa,
Bulgaria; and the recent study by Thean Hock et al. (2015),
with a Malaysian random population sample. The varying in-
cidences reported for the M2 haplotype among world popu-
lations are to be considered, but even the very recentMalaysian
study that posits a 23.6% genetic incidence of M2 with a cor-
responding 42.2% carriage rate for Malays, agrees on the risk
role of the haplotype in idiopathic women and couples who
have experienced RSA. In addition, several studies on Euro-
pean populations (Bogdanova et al., 2007; Demetriou et al.,
2015; Rogenhofer et al., 2012; Tiscia et al., 2009; Tüttelmann
et al., 2013), which in total included 944 parous female con-
trols with at least one uneventful pregnancy andwithout preg-
nancy loss, reported incidences of M2 haplotype ranging from
10 to 17% among these controls, with correspondingly el-
evated carriage rates among the clinically selected groups,
thus conﬁrming the risk role in patient cohorts with idio-
pathic RSA.
Discussion of expression studies
Historically, reporter gene assays in a functionally represen-
tative cell line delivered the ﬁrst evidence on the physiologi-
cal action of the M2 haplotype (Bogdanova et al., 2007). In
later studies on chorions carrying the M2 haplotype, reduced
ANXA5mRNA abundance was shown, which was conﬁrmed to
be haplotype speciﬁc, and concomitantly lowered ANXA5
protein levels have been detected in placental tissue of M2
carrierswith a thrombophilic placental complication.Nagirnaja
et al. (2015) discuss a counter example of a single study that,
in their opinion, demonstrates increased ANXA5 plasma levels
depending on M1 haplotype in healthy individuals (Hiddink
et al., 2012). The “signiﬁcant impact” ofM1/ANXA5 in Dutch
control paraticipants discussedbyHiddink et al. (2012), is based
on only six homozygous samples in total, with two of them
showing twice as high plasma levels as the other four. One
should exercise caution in making a justiﬁed conclusion from
these data.
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Conceptual deﬁnition
In their study arriving at the negative association results for
M2/ANXA5 in selected women who had experienced RSA and
fertile controls of Estonian and Danish extraction, Nagirnaja
et al. (2015) reach an ambitious conclusion about risk absence
in Northern Europe. In an earlier association study by Fishel
et al. (2014; citing Nelis et al., 2009), four European areas
with differing population structures that could affect the sig-
niﬁcance of disease-gene associations were outlined: Central
and Western Europe; the Baltic countries, Poland and Western
Russia; Finland; and Italy. For three of these regions, the in-
cidence in controls from Germany, Southern Italy and Bul-
garia have all shown consistency in the M2 haplotype
frequency, conﬁrmed by the recent study by Demetriou et al.
(2015) on the UK White European population. Subsequent to
Nelis et al. (2009), a further study of Northern European popu-
lations has revealed genetic diversity in the Northern Euro-
pean population, Estonians having a relatively high proportion
of Finnish ancestry (Khrunin et al., 2013). Also, there seems
to be signiﬁcant genetic diversity in North Eastern Europe.
As previous and current M2 association studies did not include
individuals of Finnish ancestry, the question of speciﬁc popu-
lation structuring that can be raised from work of Nagirnaja
et al. (2015) remains open. Most recently a study on Danish
population structure reported strong genetic inﬂuence from
neighbouring Nordic (Sweden and Norway) and Germanic
(Germany and Holland) countries and negligible inﬂuence from
Finland, France and Portugal (Athanasiadis et al., 2015). So
the grouping of Estonian and Danish participants together in
a disease association study as representatives of “Northern
Europe” seems questionable, as the Finns are well known to
be genetically different. Therefore, the indicated Estonian
incidence of the M2 haplotype in fertile controls and women
who have experienced RSA may well differ from previously
reported European populations.
Nagirnaja et al. (2015) claim, that there is a “high world-
wide prevalence” of the M2 haplotype in population-based
samples and “decreased or similar occurrence” among women
who have experienced RSA, is just not supported by the actual
studies, the only exceptions being their own study and a
Chinese study for East China, where genotyping information
seems to be missing or incomplete. Along these lines, M2/
ANXA5 seems to be possibly protective and at best neutral
to RSA in Estonian and Danish participants; however, consid-
ering the reduced prevalence in patient cohorts compared with
the fertile controls, and contrary to all previous and current
association studies except one, it would be tempting to con-
clude there might be an evolutionary advantage for M2 car-
riers. This is suggested for the offspring of M2 carrying couples
in the recent work by Demetriou et al. (2015). Although this
may be a valid conclusion, another plausible explanation could
be provided by a recent model developed for complex dis-
eases that shows that causative inherited genetic lesions may
well be more frequent in the unaffected (control) than in the
affected (patient) portion of a population, thereby appear-
ing “protective”, rather than “predisposing” in an epidemio-
logical sense (Siegert et al., 2015). This ﬁnding might seem
to be counterintuitive, but the phenomenon results from con-
founding of the disease association of one genetic lesion by
the absence of other lesions necessary for the former to exert
its effect in a given individual. In other words, for a given mu-
tation to become phenotypically expressed as a disease phe-
notype, a second genetic alteration would be necessary that
is normally present in a model population as “background”.
In a different populace however, because of population struc-
turing (confounding and admixing effects), this particular
“background” mutation could be missing from the original
group of source dwellers but then come in generations later
through the inﬂuence of another ethnic group. The model is
empirically supported by observations of negative correla-
tions between odds ratios and disease prevalence in pub-
lished genome-wide association studies. Such negative
correlations of causative genetic defects would potentially
arise as a result of the heritage tree structure of the human
gene genealogy. Therefore, population structuring could be
a relevant issue for the study by Nagirnaja et al. (2015), in
which a negative correlation may be demonstrated by the
above mechanism of confounding.
A negative M2 haplotype association with early RSA, seems
to be caused by the high prevalence of chromosomal abnor-
malities as discussed above. As the proportion of such chro-
mosomal lesions inherited from the parents is tiny (<1%), a
possible prospective study eliminating this issue would use
rapid genotyping of post-conceptuses using microarrays or
quantitative ﬂuorescence polymerase chain reaction for nega-
tive selection of aneuploidies and submicroscopic aberra-
tions among patient cohorts. Therefore, it is worth mentioning
that almost all recent association studies on the M2 haplo-
type (Rogenhofer et al., 2012; Tiscia et al., 2012; Tüttelmann
et al., 2013; Demetriou et al., 2015; Thean Hock et al., 2015)
have excluded both fetal and parental chromosomal aberra-
tions (for most studies numerical) and come to the same M2
incidence in their early RSA samples.
Genetic association studies, with properly selected patient
and control groups, are a valid approach to deliver evi-
dence on a risk factor; however, the ultimate proof of such
risk, possibly conferred by M2 carriage, would be data derived
from a randomized observational trial comparing live birth
and spontaneous abortion rates in untreated M2 carriers with
untreated non-carriers of the haplotype. Until such data are
available, no deﬁnite proof can be generated on the pro-
posed risk role of M2/ANXA5 for RSA and thrombophilia-
related obstetric complications.
Minor issues
Use of restriction fragment length polymorphism
analysis for genotyping
It is somewhat puzzling that Nagirnaja et al. (2015) opted to
use restriction fragment length polymorphism (RFLP), de-
scribed as the genotyping option in Figure 1c by Bogdanova
et al. (2007), on the Danish sample set of their participants
involving 227 patients and 115 controls. A comparison of valid
genotyping methods is deﬁnitely not in favour of RFLP as it
is prone to errors, and therefore of limited reliability (Bianchi
et al., 2010). Although this seems a minor issue assuming that
the genotyping deviation through RFLP would not exceed 5%,
valid comparisons to previously published work seem prob-
lematic because this analysis accounts for the M2 haplotype
only, thus rendering concomitant promoter genotypes
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reconstruction and genetic equilibrium calculations impos-
sible, which in turn could verify the accuracy of genotyping.
Re-sequencing of the ANXA5 proximal promoter
region in Estonian patients who have experienced
RSA and fertile controls
As stated in their results section, the Nagirnaja et al. (2015)
conﬁrm the four SNPs building the M2 haplotype in a single
linkage disequilibrium block. They also added a ﬁfth up-
stream SNP to their analysis: 180 C/T (rs62319820), which ac-
cording to a statement in the second paragraph of their results
section and to the legend of, gives identical linkage disequi-
librium results when phasing together with the M2 haplo-
type. This statement is, however, not supported by Fig. 1c
(Nagirnaja et al., 2015), showing clearly different r2 scores
for rs62319820, which seems to associate at best and only par-
tially with the M1 haplotype.
Comparative genotyping datasets of worldwide
cohorts
Nagirnaja et al. (2015) presented a summary on compara-
tive genotyping data of their Estonian and Danish cohorts in.
Although the genotype fractions from their own cohorts do
not add up to 100%, whicn can be interpreted as rounding
error, this error increases from 0.4% to 9.4% in the world-
wide datasets, raising the possibility of missing data. In ad-
dition, the cited study by Hayashi et al. (2013) that used
merged controls of different regions in Japan is incorrectly
referred to as representative for the population of Central
Japan. As previously discussed, this study delivered inﬂated
M2 prevalence values, compared with the study by Miyamura
et al. (2011) for Central Japan. Altogether, it seems that
Nagirnaja et al. (2015) used accurate software for polymor-
phism identiﬁcation, which was followed by manual check-
ing; however, the results of their procedure summarized in
Table 4 (Nagirnaja et al., 2015) leave reasons for doubt.
Conclusion
It is not a mutually exclusive option that a North–South Eu-
ropean population distribution gradient may exist for the M2
haplotype, similar to other common genetic lesions (Nelis
et al., 2009). Therefore, it might be difﬁcult to replicate pre-
vious association ﬁndings in a speciﬁc population, because of
genealogy-actuated negative correlation between caus-
ative mutations in complex disease (Siegert et al., 2015). In
conclusion, it is our opinion that a risk role attributable to
the M2 haplotype of the ANXA5 gene for idiopathic RSA cannot
be excluded or disproved from the data presented by Nagirnaja
et al. (2015).
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